Bifenthrin is a pyrethroid insecticide used in urban and agricultural applications. Bifenthrin is a broad-spectrum insecticide that modifies voltage-gated ion channels disrupting the normal function of nerve cells. In May 2010 EU Commission withdrawn plant protection products containing bifenthrin.

Tilomisole (also known as Wy-18,251) is a benzimidazole derivative patented by American Home Products Corp. as an antineoplastic agent with immunomodulating and antimetastatic activity. Tilomisole significantly enhanced the blastogenic response of cancer patients' lymphocytes in vitro. Tilomisole significantly increases macrophage phagocytosis against 51chromium labeled opsonized chicken red blood cells. In preclinical models, Tilomisole administration significantly increases peripheral blood lymphocytes in rats and demonstrates marked anti-inflammatory activity. The acute anti-inflammatory of Tilomisole.) was similar to aspirin, but in contrast to aspirin, Tilomisole failed to demonstrate antipyretic activity. Tilomisole also inhibited chronic inflammatory responses in the adjuvant- and collagen-induced arthritis models. Unfortunately, in clinical trials, Tilomisole failed to demonstrate significant antitumor responses.

Leukotriene B4 is a pro-inflammatory mediator synthesized in myeloid cells from arachidonic acid. Leukotriene B4 induces recruitment and activation of neutrophils, monocytes and eosinophils. It also stimulates the production of a number of proinflammatory cytokines and mediators indicating an ability to augment and prolong tissue inflammation. Elevated levels of leukotriene B4 have been found in a number of inflammatory diseases and levels are related to disease activity in some of these. Leukotriene B4 has a central role in metabolic dysfunctions. By increasing MyD88 expression, leukotriene B4 enhances macrophage response to TLR/IL1 receptor agonists potentiating the sterile inflammation, a central event in metabolic disease progression. Thus, leukotriene B4 is a potential therapeutic target for the treatment of metabolic disorders. Leukotriene B4 could serve as a biomarker for evaluating bestatin efficacy in colorectal cancer.

Cloquinate is an amoebicidal drug, discovered in the 1950s. It is a salt of 7-iodo-8-oxyquinoline-5-sulfonic acid (Yatren) with resochin. Cloquinate was marketed by Bayer under tradename Resotren. In clinical trials, it was demonstrated to treat abdominal and hepatic symptoms of amoebiasis.

Sipoglitazar (TAK 654) was a novel, azolealkanoic acid derivative that possesses selective activity for the peroxisome proliferator-activated receptors (PPAR) PPARγ, PPARα, and PPARδ. Sipoglitazar was developed to improve peripheral insulin sensitivity, normalize circulating lipid profiles, and reduce body weight in patients with metabolic syndrome and type 2 diabetes mellitus (T2DM). Sipoglitazar was being developed by Takeda for the treatment of diabetes mellitus, however in September 2006, development was discontinued.

Irosustat is a first-generation, orally active, irreversible steroid sulfatase inhibitor. It did not stimulate the growth of estrogen-sensitive MCF-7 breast cells in vitro. Irosustat was in phase II clinical trials for the treatment of breast cancer and endometrial cancer and phase I clinical trial for the treatment of prostate cancer. However, this research has been discontinued.

Roxolonium, a derivative of glycyrrhetic acid, was studied as an antiulcer agent. Information about the further development of this compound is not available.

Deferitazole is an iron chelator, developed by the FerroKin BioSciences (later acquired by Shire, and then by Takeda). Deferitazole is a member of the desazadesferrithiocin class of siderophore-related tridentate chelators. It binds Fe(III) with very high affinity and selectivity over Fe(II) and other biologically important metals. Deferitazole was investigated in phase 2 clinical trials in patients with iron overload due to repeated red blood cell transfusion and beta-thalassemia, however, the development of the drug was discontinued. In preclinical models, deferitazole demonstrated efficacy for the treatment and prevention of malaria.

Lorglumide (CR1409) is the first nonpeptidic, selective and potent inhibitor of the cholecystokinin-A and cholecystokinin-B receptors. Lorglumide prevented dose-dependently the emptying of the gallbladder in both experimental models; proglumide exhibited a comparable activity at much higher doses. Lorglumide was associated with significantly inhibited cell growth of human pancreatic cancer cell line Mia PaCa-2 in vitro. Lorglumide also induced G0/G1 cell cycle arrest and apoptosis. The change of invasion ability appeared to be mediated by MMP-2 expression, which was upregulated by CCK-8S and downregulated by lorglumide. Lorglumide had been in preclinical phase for the treatment of biliary dyskinesia, pancreatitis and cancer. However, this development was discontinued.

Lopobutan is an antiseptic agent.